Yousif Capital Management LLC Sells 14,784 Shares of Pfizer Inc. (NYSE:PFE)

Yousif Capital Management LLC reduced its position in shares of Pfizer Inc. (NYSE:PFE) by 2.2% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 650,247 shares of the biopharmaceutical company’s stock after selling 14,784 shares during the period. Yousif Capital Management LLC’s holdings in Pfizer were worth $17,251,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Silverlake Wealth Management LLC grew its position in shares of Pfizer by 8.4% during the 4th quarter. Silverlake Wealth Management LLC now owns 76,689 shares of the biopharmaceutical company’s stock worth $2,035,000 after buying an additional 5,966 shares during the period. Sargent Investment Group LLC grew its holdings in Pfizer by 7.1% during the fourth quarter. Sargent Investment Group LLC now owns 8,093 shares of the biopharmaceutical company’s stock valued at $217,000 after purchasing an additional 536 shares during the period. Old North State Wealth Management LLC boosted its holdings in shares of Pfizer by 23.6% in the fourth quarter. Old North State Wealth Management LLC now owns 79,441 shares of the biopharmaceutical company’s stock valued at $2,109,000 after buying an additional 15,194 shares during the period. James J. Burns & Company LLC boosted its holdings in shares of Pfizer by 4.2% in the fourth quarter. James J. Burns & Company LLC now owns 14,912 shares of the biopharmaceutical company’s stock valued at $396,000 after buying an additional 605 shares during the period. Finally, Stephens Consulting LLC boosted its holdings in shares of Pfizer by 66.1% in the fourth quarter. Stephens Consulting LLC now owns 5,826 shares of the biopharmaceutical company’s stock valued at $155,000 after buying an additional 2,318 shares during the period. 68.36% of the stock is owned by institutional investors.

Pfizer Price Performance

NYSE:PFE opened at $25.88 on Wednesday. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54. The company has a market cap of $146.64 billion, a P/E ratio of 34.97, a P/E/G ratio of 0.66 and a beta of 0.64. The firm’s fifty day moving average price is $26.27 and its two-hundred day moving average price is $27.82. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The firm had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. During the same period in the previous year, the company earned $0.10 earnings per share. The company’s quarterly revenue was up 24.7% on a year-over-year basis. Equities analysts expect that Pfizer Inc. will post 2.96 earnings per share for the current year.

Pfizer Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be paid a $0.43 dividend. The ex-dividend date is Friday, January 24th. This is an increase from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a dividend yield of 6.65%. Pfizer’s dividend payout ratio is 232.44%.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. StockNews.com cut shares of Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Wolfe Research initiated coverage on shares of Pfizer in a research report on Friday, November 15th. They issued an “underperform” rating and a $25.00 price objective on the stock. Evercore ISI raised shares of Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. Sanford C. Bernstein initiated coverage on shares of Pfizer in a research report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price objective on the stock. Finally, Truist Financial cut their price objective on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, December 18th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Pfizer presently has a consensus rating of “Moderate Buy” and a consensus price target of $31.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.